Long-Term Thesis

Long-Term Thesis — 5-to-10-Year View

The long-term thesis is that DMP is the second-largest unit of the global Domino's system holding contract-protected master-franchise rights in 12 markets, and the next decade is worth owning only if the next operating team closes most of the 760 basis point EBITDA-margin gap to DOM (UK) on the same brand, MFA and technology stack. The 5-to-10-year case works only if franchisee EBITDA per store reverts from the FY25 group average of A$95k back toward management's A$130k target, network growth restarts in Asia and Europe, and the balance sheet deleverages below 2.0x net debt to underlying EBITDA. This is not a long-duration compounder unless the new CEO can demonstrate, within two or three reporting cycles, that the underperformance outside ANZ is execution rather than structural mix — and the MFA with DPZ stays unconditional through the closure cycle. The single durable variable that decides everything else is whether the master franchisee can earn its cost of capital in all twelve markets, not just one.

1. The 5-to-10-Year Underwriting Map

Six drivers carry the long-term case. Each requires both observable validating evidence today and a clearly named failure pattern that would refute it. The bar for confidence is deliberately high — these are 5-to-10-year claims, not next-print read-throughs.

The driver that matters most is margin convergence toward DOM — every other line in the table is either a precondition for that convergence (MFA, runway, balance sheet) or a derivative of it (ANZ continues to drive group profit only if Europe and Asia stop bleeding). The convergence question collapses to a simpler one: is the 760bps gap structural mix (corporate-store overhang, sub-scale European commissaries, developed-Asia mass-market exposure) or is it execution that an externally-recruited operator can close? DOM ran the same brand for a decade before its current margin level; the answer is not in the FY25 result, it is in the next three.

2. Compounding Path

The long-term value of DMP is the combined operation of all twelve markets through a full cycle, not a sum-of-the-parts. The compounding path lives in three numbers: same-store-sales growth at low-single digits, EBITDA margin recovery into the low teens, and modest network growth concentrated in Asia ex-Japan and Europe ex-France. None of those alone is sufficient; together they convert today's underlying EBITDA of A$280m into A$380-450m by FY30, and they re-establish the right to a master-franchisee multiple of 13-15x rather than a QSR-operator multiple of 11x.

The compounding path is margin-led, not revenue-led — total revenue rises only ~3% per year, but EBITDA roughly doubles because each new percentage point of EBITDA margin on a A$2.4bn base adds A$24m of EBITDA without commensurate capital. Free cash flow conversion is the structurally strong part of the model: D&A around A$110m per year, capex normalising back toward A$60-80m, leaves A$160-200m of annual discretionary FCF in the base case. That funds two outcomes simultaneously — deleveraging below 2.0x and a moderate dividend — without requiring an equity issuance. The balance-sheet capacity is the binding constraint on how fast the path can be funded, not whether it can be funded at all.

ROIC is the cleanest test of whether the compounding works. At FY21's 12.3% the business was earning ~3x its cost of capital on incremental dollars. The collapse to -3.5% in FY25 is partly cyclical (closure charges, Japan impairments) and partly structural (FY23 A$377m Asia acquisition at peak multiple, deteriorating franchisee economics). For the long-term thesis to work, ROIC needs to climb back to 8-10% by FY28 — the level at which a master franchisee earns more than its cost of capital and the multiple supports re-rating. Below 6% sustained ROIC, the multiple stays operator-grade.

3. Durability and Moat Tests

Five tests determine whether the moat that exists in ANZ — contractual exclusivity, density, supply chain, brand — can survive a decade of competitor offence, technology shift, and the natural drift of any franchise system. Two of these tests are competitive, two are financial, and one is contractual. Each has a validation signal and a refutation signal that an investor can monitor cleanly.

The MFA test is existential and the margin-gap test is decisive. Everything else either reinforces or undermines those two. A wide-moat business should pass all five tests over a decade; DMP passes the ANZ share test, currently fails the margin-gap test, has open exposure on the MFA test, and is in slow erosion on the aggregator test. The financial-leverage test is on a clear improvement track if EBITDA recovers. That asymmetry — one fortress, three contested, one slow-burn — is what the "narrow moat" label means in long-duration terms.

4. Management and Capital Allocation Over a Cycle

Long-term value compounds when management defends the franchisee P&L through the cycle, applies capital where the marginal dollar earns above cost, and resists the temptation to use the income statement for narrative purposes. DMP's record across the FY19-FY25 cycle is mixed. The decade through FY22 was characterised by aggressive store growth ambition — the "double the footprint in a decade" promise, the FY19 Japan store-count target raised from 850 to 1,000, the FY21 ANZ 1,200-store target — most of which have since been quietly retracted. The Asia acquisition in FY23 (A$377m for Malaysia/Singapore/Cambodia) was deployed at a peak multiple into markets that have not yet earned their cost of capital, and the FY25 closure programme (312 stores including 233 in Japan) is the direct consequence. ROIC fell from 12.3% in FY21 to -3.5% in FY25 — the clearest single indictment of the cycle.

What the data shows on the way down is more encouraging. Capex was slashed from A$108m (FY23) to A$29m (FY25) without an immediate revenue penalty, acquisitions essentially halted, the dividend was cut 56% from A$1.735 to A$0.77, and management has held debt repayment as the top priority. The FY22 LTI plan vested at zero and FY25 STI was forfeited 87.5% — the board has not been rubber-stamping pay during the downturn. Founder Jack Cowin (26% ownership) bought A$5.06m on-market at A$15.11 in August 2025, the largest disclosed insider buy in the register, against a backdrop where no other executive opened the chequebook.

Three judgments matter for the next decade. First, the Asia acquisition was a capital error of magnitude — A$377m deployed at peak multiple into markets that still earn below cost of capital — and the long-term thesis must price this in rather than around it. Second, the FY25 reset shows the board can defer to discipline when the data demands it, which is the kind of cycle-aware behaviour that adds long-term value. Third, the governance overhang is real but bounded: founder ownership of 26% is alignment, the related-party purchases (A$24.7m in FY25 from Cowin-affiliated food businesses) are watched but not yet abusive, and the Independent Board Committee formed July 2025 is the right structural response if it is given real authority. The single capital-allocation question for FY26 onward is what Gregory does in his first 100 days — and specifically whether he sets quantified margin-convergence targets that the market can verify rather than another store-count ambition.

5. Failure Modes

The red-team list. These are the specific paths through which the 5-to-10-year thesis fails — not generic "execution risk" but observable, dated failure modes with early-warning signals.

6. What To Watch Over Years, Not Just Quarters

Five multi-year milestones — each with a metric, a time horizon, what would validate the thesis, and what would weaken it. The first one absorbs most of the others.

The long-term thesis changes most if the group EBITDA margin sustains above 12% for two consecutive fiscal years with significant items below A$20m — that single multi-year signal converts DMP from a narrow-moat franchise system in repair into a system that has earned the right to a master-franchisee multiple, validates the MFA, and re-establishes ROIC above cost of capital across all twelve markets. Without it, every other line in this report is a near-term observation rather than a long-duration thesis.